HAL spectacle lens
DeviceHAL spectacle lens for myopia control
NCT Number: NCT07668102
To evaluate the visual performance of (high and low contrast distance visual acuity, reading speed, near visual acuity, and near contrast sensitivity) of HAL spectacle lenses (habitual correction) in comparison with single vision control lenses.
Looking for future studies?
Notify Me6 year–12 year
All sexes
Interventional
Not applicable
Scripps Poway Optometry, San Diego, California, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
HAL spectacle lens for myopia control
Single vision spectacle lens for myopia and astigmatism correction
Time frame: Between Year 1 and Year 2 of the WS10246 study, representing an average timeframe of 1.5 years into the parent study.
Reading speed (mean words per minute) collected using the Wolffsohn Research iPad OptomCentral App
Time frame: Between Year 1 and Year 2 of the WS10246 study, representing an average timeframe of 1.5 years into the parent study.
Measured to the nearest letter using a standard ETDRS chart at 4 meters.
Time frame: Between Year 1 and Year 2 of the WS10246 study, representing an average timeframe of 1.5 years into the parent study.
Evaluated at 40 cm using the iPad OptomCentral App across various spatial frequencies to calculate the Area Under the Log Contrast Sensitivity Function (AULCSF).
Looking for future studies?
Notify MeEssilor International
Industry
Clinical Evaluation of Vision Performance of the FIN C2 Lens
Acronym: FIN-3102
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05320042
Astigmatism, Eye Diseases
Rochester, New York, United States
View Trial DetailsNCT07284966
Astigmatism, Eye Diseases
San Diego, California, United States
View Trial DetailsNCT06817785
Eye Diseases, Myopia
Waterloo, Ontario, Canada
View Trial DetailsNCT07780851
Eye Diseases, Myopia
Singapore
View Trial Details